Avastin sBLA Submission Means Breast Cancer Pricing Could Be Set By November
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech is seeking a six-month priority review for bevacizumab in breast cancer.
You may also be interested in...
Genentech To Resubmit Avastin sBLA In Mid-2007
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.
Genentech To Resubmit Avastin sBLA In Mid-2007
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.
FDA Requests Additional Information Regarding Avastin Breast Cancer Application
Genentech says the agency is seeking additional information regarding progression-free survival.